Through our upcoming fireside chat with Perficient’s Mike Grossman, GM, Life Sciences, and Oracle’s Jim Streeter, Global VP, Life Sciences Product Strategy, we are really aiming to clarify some fundamental questions relating to Oracle’s Clinical One and what this platform approach could mean for our clients.
They are going to get right back to the basics of why it is beneficial to invest time and money implementing a unified platform rather than continuing to upgrade individual systems for data capture, randomization, trial management, etc. What would the transition to a unified platform involve? How would a company get started on this journey? Is it possible to transition one functionality at a time?
If there are questions that you would like to have addressed about Clinical One, by all means, let me know or come along and submit them during the session.
I encourage you to attend to hear directly from the Global VP responsible for Clinical One. You can register here or click on the banner below.
We are also preparing for a webinar in October in which we will, again, be working with Oracle to demo Clinical One and further discuss the roadmap and what the transition to Clinical One would look like.
One thing we know for sure is that to achieve success, moving away from legacy solutions like IVRS/RTSM, EDC, and CTMS is going to require business process optimization and change management.
